116 related articles for article (PubMed ID: 18670318)
1. Drug interaction between complementary herbal medicines and gefitinib.
Hwang SW; Han HS; Lim KY; Han JY
J Thorac Oncol; 2008 Aug; 3(8):942-3. PubMed ID: 18670318
[No Abstract] [Full Text] [Related]
2. Two rare exon 21 EGFR mutations in patients treated with gefitinib.
Mompradé E; Arriola E; Martínez-Avilés L
J Thorac Oncol; 2013 Apr; 8(4):e36-7. PubMed ID: 23486275
[No Abstract] [Full Text] [Related]
3. Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma.
Wagner M; Besse B; Balleyguier C; Soria JC
J Thorac Oncol; 2008 Jun; 3(6):677-9. PubMed ID: 18520813
[No Abstract] [Full Text] [Related]
4. Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.
Wu SG; Shih JY; Yu CJ; Yang PC
J Thorac Oncol; 2008 Apr; 3(4):451-2. PubMed ID: 18379370
[No Abstract] [Full Text] [Related]
5. Lung cancer response to gefitinib, then erlotinib, then gefitinib again.
Wong AS; Seto KY; Chin TM; Soo RA
J Thorac Oncol; 2008 Sep; 3(9):1077-8. PubMed ID: 18758318
[No Abstract] [Full Text] [Related]
6. Surgical resection of lung adenocarcinoma without EGFR mutation after neoadjuvant gefitinib treatment.
Shen H; Zhong X; Ge XQ; Huang JJ; Yuan Y
Clin Respir J; 2010 Jul; 4(3):192-3. PubMed ID: 20565499
[No Abstract] [Full Text] [Related]
7. A case of advanced non-small-cell lung cancer who responded slowly to gefitinib monotherapy after long-term disease stabilization.
Hotta K; Kiura K; Shirahige A; Takata S; Takigawa N; Tabata M; Watanabe H; Tanimoto M
Acta Oncol; 2009; 48(3):471-3. PubMed ID: 18855159
[No Abstract] [Full Text] [Related]
8. First case of A859T epidermal growth factor receptor mutation responding to erlotinib.
Le Maignan L; Mirebeau-Prunier D; Vervueren L; Jeanfaivre T; Urban T; Hureaux J
J Thorac Oncol; 2011 Mar; 6(3):639-40. PubMed ID: 21317745
[No Abstract] [Full Text] [Related]
9. Good response to gefitinib for lung adenocarcinoma with hyperamylasemia: a case report.
Ko HW; Tsai YH; Yu CT; Huang CY; Chen CH
Chang Gung Med J; 2008; 31(6):606-11. PubMed ID: 19241901
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis?
Chen WC; Chen W; Tseng GC; Lai HC; Shih CM; Hsia TC
Liver Int; 2010 Nov; 30(10):1548-9. PubMed ID: 20345702
[No Abstract] [Full Text] [Related]
11. EGFR exon 19 insertions show good response to gefitinib, but short time to progression in Japanese patients.
Park J; Kondo C; Shimizu J; Horio Y; Yoshida K; Hida T
J Thorac Oncol; 2014 Feb; 9(2):e10-1. PubMed ID: 24419426
[No Abstract] [Full Text] [Related]
12. Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case?
Giovannini M; Belli C; Villa E; Gregorc V
J Thorac Oncol; 2008 Jun; 3(6):684-5. PubMed ID: 18520816
[No Abstract] [Full Text] [Related]
13. Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.
Iyevleva AG; Mitiushkina NV; Karaseva NA; Orlov SV; Volodina LN; Kulikova YE; Lozhkina AM; Ivantsov AO; Tiurin VI; Togo AV; Imyanitov EN
J Thorac Oncol; 2014 Apr; 9(4):e31-3. PubMed ID: 24736087
[No Abstract] [Full Text] [Related]
14. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
Vasile E; Tibaldi C; Chella A; Falcone A
J Thorac Oncol; 2008 Aug; 3(8):912-4. PubMed ID: 18670311
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
Katayama T; Shimizu J; Suda K; Onozato R; Fukui T; Ito S; Hatooka S; Sueda T; Hida T; Yatabe Y; Mitsudomi T
J Thorac Oncol; 2009 Nov; 4(11):1415-9. PubMed ID: 19692934
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.
DeGrendele H
Clin Lung Cancer; 2003 Sep; 5(2):83-5. PubMed ID: 14596689
[No Abstract] [Full Text] [Related]
17. Increasing osteoblastic lesions as a manifestation of a major response to gefitinib.
Garfield D
J Thorac Oncol; 2006 Oct; 1(8):859-60. PubMed ID: 17409972
[No Abstract] [Full Text] [Related]
18. Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.
Gridelli C; Maione P; Galetta D; Colantuoni G; Del Gaizo F; Ferrara C; Guerriero C; Nicolella D; Rossi A
J Thorac Oncol; 2007 Aug; 2(8):758-61. PubMed ID: 17762344
[TBL] [Abstract][Full Text] [Related]
19. Improvement of psoriasis in a lung cancer patient treated with erlotinib.
Giroux Leprieur E; Friard S; Couderc LJ
Eur J Dermatol; 2010; 20(2):243-4. PubMed ID: 20123646
[No Abstract] [Full Text] [Related]
20. Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
Pennell NA; Yin L; Keshtgarpour M; Ma PC
J Thorac Oncol; 2012 Jul; 7(7):1200-1. PubMed ID: 22706608
[No Abstract] [Full Text] [Related]
[Next] [New Search]
